These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Modeling of drug release from celecoxib-PVP-meglumine amorphous systems. Gupta P; Bansal AK PDA J Pharm Sci Technol; 2005; 59(6):346-54. PubMed ID: 16471422 [TBL] [Abstract][Full Text] [Related]
6. Formulation, characterization, and in vivo evaluation of celecoxib-PVP solid dispersion nanoparticles using supercritical antisolvent process. Ha ES; Choo GH; Baek IH; Kim MS Molecules; 2014 Dec; 19(12):20325-39. PubMed ID: 25486246 [TBL] [Abstract][Full Text] [Related]
7. Spray drying for generation of a ternary amorphous system of celecoxib, PVP, and meglumine. Gupta P; Bansal AK Pharm Dev Technol; 2005; 10(2):273-81. PubMed ID: 15926676 [TBL] [Abstract][Full Text] [Related]
8. Physicochemical properties of tadalafil solid dispersions - Impact of polymer on the apparent solubility and dissolution rate of tadalafil. Wlodarski K; Sawicki W; Haber K; Knapik J; Wojnarowska Z; Paluch M; Lepek P; Hawelek L; Tajber L Eur J Pharm Biopharm; 2015 Aug; 94():106-15. PubMed ID: 25998701 [TBL] [Abstract][Full Text] [Related]
9. Anomalous dissolution behavior of celecoxib in PVP/Isomalt solid dispersions prepared using spray drier. Ghanavati R; Taheri A; Homayouni A Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():501-511. PubMed ID: 28024614 [TBL] [Abstract][Full Text] [Related]
10. Impact of surfactants on the crystal growth of amorphous celecoxib. Mosquera-Giraldo LI; Trasi NS; Taylor LS Int J Pharm; 2014 Jan; 461(1-2):251-7. PubMed ID: 24333451 [TBL] [Abstract][Full Text] [Related]
11. Physicochemical properties of direct compression tablets with spray dried and ball milled solid dispersions of tadalafil in PVP-VA. Wlodarski K; Tajber L; Sawicki W Eur J Pharm Biopharm; 2016 Dec; 109():14-23. PubMed ID: 27658987 [TBL] [Abstract][Full Text] [Related]
12. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles. Fini A; Cavallari C; Ospitali F Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516 [TBL] [Abstract][Full Text] [Related]
13. Comparing various techniques to produce micro/nanoparticles for enhancing the dissolution of celecoxib containing PVP. Homayouni A; Sadeghi F; Varshosaz J; Garekani HA; Nokhodchi A Eur J Pharm Biopharm; 2014 Sep; 88(1):261-74. PubMed ID: 24952357 [TBL] [Abstract][Full Text] [Related]
14. Hydroxypropyl cellulose stabilizes amorphous solid dispersions of the poorly water soluble drug felodipine. Sarode AL; Malekar SA; Cote C; Worthen DR Carbohydr Polym; 2014 Nov; 112():512-9. PubMed ID: 25129775 [TBL] [Abstract][Full Text] [Related]
15. Stability and solubility of celecoxib-PVP amorphous dispersions: a molecular perspective. Gupta P; Kakumanu VK; Bansal AK Pharm Res; 2004 Oct; 21(10):1762-9. PubMed ID: 15553220 [TBL] [Abstract][Full Text] [Related]
16. Use of calcined Mg-Al-hydrotalcite to enhance the stability of celecoxib in the amorphous form. Ambrogi V; Perioli L; Marmottini F; Rossi C Eur J Pharm Biopharm; 2007 May; 66(2):253-9. PubMed ID: 17123798 [TBL] [Abstract][Full Text] [Related]
17. Study on mechanism for amorphous drug stabilization using gelucire 50/13. Shimpi SL; Mahadik KR; Paradkar AR Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):937-42. PubMed ID: 19721253 [TBL] [Abstract][Full Text] [Related]
18. Wettability and surface chemistry of crystalline and amorphous forms of a poorly water soluble drug. Puri V; Dantuluri AK; Kumar M; Karar N; Bansal AK Eur J Pharm Sci; 2010 May; 40(2):84-93. PubMed ID: 20230893 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of drug-excipient interaction in the formulation of celecoxib tablets. Bozdağ-Pehlivan S; Subaşi B; Vural I; Unlü N; Capan Y Acta Pol Pharm; 2011; 68(3):423-33. PubMed ID: 21648198 [TBL] [Abstract][Full Text] [Related]
20. Effect of Variability of Physical Properties of Povidone K30 on Crystallization and Drug-Polymer Miscibility of Celecoxib-Povidone K30 Amorphous Solid Dispersions. Phadke C; Sharma J; Sharma K; Bansal AK Mol Pharm; 2019 Oct; 16(10):4139-4148. PubMed ID: 31454247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]